ALLMedicine™ Thrombotic Thrombocytopenic Purpura Center

Mar 2nd, 2021 - Pregnancy seems to increase the risk of thrombotic thrombocytopenic purpura (TTP) relapses and make the TTP more severe in any of the pregnancy trimesters, or even during the postpartum period. This study highlights details of treating a COVID-19 ...

Mar 2nd, 2021 - Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare thrombotic microangiopathy characterized by severe congenital ADAMTS13 deficiency and recurring acute episodes causing morbidity and premature death. Information on the annual inciden...

Mar 1st, 2021 - Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.|2021|Hrdinová J,D'Angelo S,Graça NAG,Ercig B,Vanhoorelbeke K,|

Feb 23rd, 2021 - Thrombotic Thrombocytopenic Purpura (TTP), a rare, potentially life-threatening thrombotic microangiopathy, manifests as both congenital (cTTP) and acquired forms. It is caused by the absence of or severe depletion in a disintegrin and metalloprot...

Feb 22nd, 2021 - Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunatel...

Feb 5th, 2019 - CABLIVI is a von Willebrand factor (vWF)-directed antibody fragment indicated for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura (aTTP), in combination with plasma exchange and immunosuppressive therapy.

Feb 5th, 2019 - The FDA today approved caplacizumab-yhdp injection as the first therapy specifically indicated for the treatment of adults with acquired thrombotic thrombocytopenic purpura, a rare and life-threatening blood clotting disorder.

Feb 5th, 2019 - The U.S. Food and Drug Administration (FDA) has approved Cablivi® (caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Cablivi is the firs...

Jan 23rd, 2019 - In acquired thrombotic thrombocytopenic purpura (TTP), an immune-mediated deficiency of the von Willebrand factor–cleaving protease ADAMTS13 allows unrestrained adhesion of von Willebrand factor multimers to platelets and microthrombosis, which re...

Jan 16th, 2019 - Patients with acquired thrombotic thrombocytopenic purpura (TTP) have von Willebrand factor (VWF)–mediated platelet aggregates that ...HERCULES Trial

Mar 2nd, 2021 - Pregnancy seems to increase the risk of thrombotic thrombocytopenic purpura (TTP) relapses and make the TTP more severe in any of the pregnancy trimesters, or even during the postpartum period. This study highlights details of treating a COVID-19 ...

Mar 2nd, 2021 - Hereditary thrombotic thrombocytopenic purpura (hTTP) is a rare thrombotic microangiopathy characterized by severe congenital ADAMTS13 deficiency and recurring acute episodes causing morbidity and premature death. Information on the annual inciden...

Mar 1st, 2021 - Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers.|2021|Hrdinová J,D'Angelo S,Graça NAG,Ercig B,Vanhoorelbeke K,|

Feb 23rd, 2021 - Thrombotic Thrombocytopenic Purpura (TTP), a rare, potentially life-threatening thrombotic microangiopathy, manifests as both congenital (cTTP) and acquired forms. It is caused by the absence of or severe depletion in a disintegrin and metalloprot...

Feb 22nd, 2021 - Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a rare disease in adults and exceptional in childhood. Caplacizumab has proven its effectiveness in the treatment of iTTP in adulthood in association with standard of care. Unfortunatel...

Nov 15th, 2020 - A brand-new treatment – one of the first for 25 years – for acute acquired thrombotic thrombocytopenic purpura (aTTP) has been recommended by the National Institute for Health and Care Excellence (NICE) for routine use in the NHS. Caplacizumab (Ca...

Oct 31st, 2019 - Caplacizumab-yhdp (Cablivi) Class: Monoclonal antibody fragment directed against von Willebrand factor. Disease: Thrombotic thrombocytopenic purpura.

Oct 9th, 2019 - Older patients with immune thrombotic thrombocytopenic purpura (iTTP) more often have an atypical neurological presentation, which could result in a delayed diagnosis, according to authors of a recent retrospective analysis. “Practitioners should.

Apr 25th, 2019 - GLASGOW – Neurological abnormalities and elevated troponin predict mortality in patients with thrombotic thrombocytopenic purpura (TTP), according to retrospective analysis of 475 patients from the United Kingdom TTP registry. Will Pass/MDedge New.

Apr 3rd, 2019 - GLASGOW — Combining prophylactic infusions and anti-platelet therapy normalises thrombus formation in patients with congenital thrombotic thrombocytopenic purpura (TTP) under shear flow conditions, reveals a novel assay developed by UK researchers...